Hops: Xanthohumol Research

Table of Contents

1. What Xanthohumol Is
2. What Happens to It in the Human Body
3. Weight, Blood Fats and Blood Sugar
4. A Small Human Study on Inflammation Markers
5. The Cancer Research: Cells and Animals
6. Skin and Cosmetic Research
7. Gut, Microbiome and Brain
8. A Different Hop Compound: Isohumulones and Blood Vessels
9. The Dose Gap
10. Where Each Claim Sits
11. Key Research Papers
12. Connections

What Xanthohumol Is

Xanthohumol is a prenylated chalcone, a type of flavonoid with a small fatty side chain attached. It is the principal prenylated flavonoid of the female hop cone and is made in the cone's resin-filled lupulin glands through a specialised branch of the plant's flavonoid chemistry (Stevens and Page, 2004).

It is closely related to two other hop compounds covered elsewhere on this site: isoxanthohumol, into which it converts, and 8-prenylnaringenin, the strong plant oestrogen discussed on 8-Prenylnaringenin and Menopause.

Human exposure to xanthohumol has historically come mainly from beer (Stevens and Page, 2004). Isolated xanthohumol is used in the research studies described below.

Back to Table of Contents

What Happens to It in the Human Body

The key human pharmacokinetic study gave single oral doses of 20, 60 or 180 mg of xanthohumol to 48 adults (24 men, 24 women) and measured blood levels for five days (Legette and colleagues, 2014).

• Two peaks. Blood levels peaked around one hour after the dose and again between four and five hours, a biphasic pattern the authors described as distinctive.
• Higher dose, higher exposure. Total exposure rose with dose across the three levels.
• Long-lasting. The average half-life was about 20 hours at 60 mg and 18 hours at 180 mg.
• Mostly conjugated. Xanthohumol and isoxanthohumol circulated mainly in bound (conjugated) forms, the shape the liver and gut give compounds to prepare them for excretion. 8-PN and 6-PN were undetectable in most people.

A 2022 review adds that little is known about xanthohumol's metabolism in the human body (Neumann and colleagues, 2022). This matters when reading cell studies, which commonly apply the free compound directly to cells.

Back to Table of Contents

Weight, Blood Fats and Blood Sugar

The 2014 pharmacokinetic study described xanthohumol in its title as an "antihyperglycemic" (blood-sugar-lowering) flavonoid, reflecting earlier animal work. The 2022 review of cardiometabolic effects sets out the state of play (Neumann and colleagues, 2022):

• Animals: xanthohumol had beneficial effects on body weight, lipid profile, glucose metabolism and other markers associated with metabolic syndrome and cardiovascular disease.
• Cells: laboratory studies are increasingly explaining possible mechanisms.
• People: the in-vivo results overall are "inconsistent and quantitatively insufficient", and even less is known about effects on body weight and cardiovascular risk factors in humans than about its metabolism.
• Safety: pharmacokinetic and safety studies indicate that xanthohumol intake is safe and well tolerated in animals and humans.

The review calls for studies to test whether the animal effects are reproducible in humans, and at what dose, formulation and duration. For the condition itself see Metabolic Syndrome.

Back to Table of Contents

A Small Human Study on Inflammation Markers

Can the tiny amounts of xanthohumol found in food do anything measurable? A placebo-controlled, single-blind, crossover study tested that in 14 healthy young men and women (Jung and colleagues, 2022).

• Participants drank a beverage containing 0.125 mg of xanthohumol, or a placebo drink, on separate occasions.
• White blood cells (peripheral blood mononuclear cells) were taken before and one hour after, then challenged in the laboratory with lipoteichoic acid, a component of bacterial cell walls.
• After placebo, the challenge triggered significant release of the inflammatory signals IL-1β, IL-6 and soluble CD14. After xanthohumol, the 48-hour release was not significantly higher than in unchallenged cells.
• Further cell experiments pointed to an effect involving the immune receptors CD14 and TLR2.

This is a well-designed small mechanistic study. It shows that a dietary-level dose changed how blood cells responded in a test tube an hour later. It does not show any change in illness, symptoms or long-term inflammation.

Back to Table of Contents

The Cancer Research: Cells and Animals

Xanthohumol has been called a "broad-spectrum" cancer chemopreventive agent on the basis of in vitro (test-tube) studies (Stevens and Page, 2004). A 2021 review of its anticancer properties describes it inhibiting the growth and multiplication of cancer cells by acting on many signalling pathways (Akt, AMPK, ERK, NF-κB, STAT3 and others) and on proteins controlling cell death, cell division and tissue invasion (Girisa and colleagues, 2021).

The review concludes that xanthohumol has "enormous therapeutic potential" and could be a multi-targeted anticancer agent with minimal side effects. That is the authors' forecast. The evidence it summarises is laboratory and animal work; no human cancer-prevention or cancer-treatment trial of xanthohumol appears in this citation set. Compounds that act on many pathways in cell culture can fail to reach effective concentrations in human tissue, and the pharmacokinetic study above showed that what circulates in people is mostly the conjugated form.

Cancer claims for supplements carry a particular risk: they can lead people to delay effective treatment. Decisions about cancer treatment belong with an oncology team.

Back to Table of Contents

Skin and Cosmetic Research

A 2024 review collected the dermatology findings (Kołodziejczak and colleagues, 2024). In laboratory studies xanthohumol:

• scavenged hydroxyl and superoxide free radicals;
• showed antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis and the acne bacterium Propionibacterium acnes;
• inhibited tyrosinase, the enzyme that starts melanin (pigment) production, and reduced pigment transport in pigment cells;
• reduced the inflammatory signals TNF-α, IL-6 and IL-1β from immune cells;
• lowered the activity of elastase and collagen-degrading enzymes (MMP-1, -2 and -9) and increased production of collagen types I, III and V, elastin and fibrillins in skin fibroblasts.

An earlier review of beer compounds and skin listed possible uses in eczema, contact dermatitis, pigment disorders, infections, skin ageing and sun protection, but stated plainly that direct evidence of these compounds in clinical application is lacking and that their stability and delivery through skin would first need to be solved (Chen and colleagues, 2014).

Back to Table of Contents

Gut, Microbiome and Brain

• Inflammatory bowel disease. A 2023 review of natural antioxidants for intestinal inflammation includes xanthohumol among many polyphenols (resveratrol, curcumin, quercetin and others) that act on the NF-κB and Nrf2 signalling pathways in laboratory and animal models (Sahoo and colleagues, 2023). It is one entry in a long list, not a tested treatment.
• Microbiome and cognition. A 2025 review of six randomised trials of antioxidants and the gut microbiome or brain function included xanthohumol among the polyphenols studied. It found that changes in microbiome diversity were modest and inconsistent, and that the varied studies limit any clinical conclusion (Hyży and colleagues, 2025).

Back to Table of Contents

A Different Hop Compound: Isohumulones and Blood Vessels

Not all hop research is about xanthohumol. Isohumulones (iso-alpha acids) are the main bitter compounds in beer, formed from the hop alpha acids during brewing. In a randomised crossover study, 12 cigarette smokers and 11 non-smokers took an isomerised hop extract or placebo, and their artery function was measured by ultrasound as flow-mediated dilation (FMD), the ability of an artery to widen when blood flow increases (Tomita and colleagues, 2017).

• At the start, smokers had significantly lower FMD than non-smokers.
• FMD increased significantly 30 and 120 minutes after the hop extract in both groups.
• In cultured human aortic cells, the extract protected against oxygen-starvation cell death and reduced oxidative stress triggered by angiotensin II.

The study measured a short-term effect of a single dose. Whether repeated use changes blood pressure, heart attacks or strokes was not studied.

Back to Table of Contents

The Dose Gap

A recurring problem across this literature is the gap between the doses that do something in a laboratory and the amounts people actually take in:

• The human pharmacokinetic study used up to 180 mg in a single dose (Legette and colleagues, 2014).
• The inflammation-marker study used 0.125 mg, chosen as an amount achievable through diet (Jung and colleagues, 2022).
• Cell studies commonly apply the free compound directly to cells, whereas in human blood xanthohumol circulates mainly in conjugated forms (Legette and colleagues, 2014).

Beer is sometimes presented as a way to obtain xanthohumol. Reviews state that the amounts absorbed from moderate beer drinking, and any benefit, still need to be determined (Chen and colleagues, 2014), and beer brings alcohol with it; see Alcohol.

Back to Table of Contents

Where Each Claim Sits

1. Human, measured: absorption, two-peak pattern, long half-life, conjugated forms dominate; well tolerated at single doses up to 180 mg.
2. Human, laboratory marker: reduced inflammatory response of blood cells after a dietary-level dose (one small study).
3. Human, acute vascular marker: improved artery function for two hours after isohumulones (a different hop compound).
4. Animal: improvements in weight, blood fats and blood sugar; not yet reproduced consistently in people.
5. Cell culture: anticancer, antibacterial, anti-pigment, anti-inflammatory and collagen effects.
6. Absent: any trial showing prevention or treatment of a disease in people.

Back to Table of Contents

Key Research Papers

1. Stevens JF, Page JE. Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry. 2004;65(10):1317-30. PubMed PMID: 15231405
2. Legette L, Karnpracha C, Reed RL, et al. Human pharmacokinetics of xanthohumol, an antihyperglycemic flavonoid from hops. Molecular nutrition & food research. 2014;58(2):248-55. PubMed PMID: 24038952
3. Neumann HF, Frank J, Venturelli S, et al. Bioavailability and Cardiometabolic Effects of Xanthohumol: Evidence from Animal and Human Studies. Molecular nutrition & food research. 2022;66(6):e2100831. PubMed PMID: 34967501
4. Jung F, Staltner R, Tahir A, et al. Oral intake of xanthohumol attenuates lipoteichoic acid-induced inflammatory response in human PBMCs. European journal of nutrition. 2022;61(8):4155-4166. PubMed PMID: 35857130
5. Girisa S, Saikia Q, Bordoloi D, et al. Xanthohumol from Hop: Hope for cancer prevention and treatment. IUBMB life. 2021;73(8):1016-1044. PubMed PMID: 34170599
6. Kołodziejczak A, Dziedzic M, Algiert-Zielińska B, et al. A Novel Look at Mechanisms and Applications of Xanthohumol (XN) in Dermatology and Cosmetology. International journal of molecular sciences. 2024;25(22). PubMed PMID: 39596008
7. Chen W, Becker T, Qian F, et al. Beer and beer compounds: physiological effects on skin health. Journal of the European Academy of Dermatology and Venereology : JEADV. 2014;28(2):142-50. PubMed PMID: 23802910
8. Sahoo DK, Heilmann RM, Paital B, et al. Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease. Frontiers in endocrinology. 2023;14:1217165. PubMed PMID: 37701897
9. Hyży A, Rozenek H, Gondek E, et al. Effect of Antioxidants on the Gut Microbiome Profile and Brain Functions: A Review of Randomized Controlled Trial Studies. Foods (Basel, Switzerland). 2025;14(2). PubMed PMID: 39856843
10. Tomita J, Mochizuki S, Fujimoto S, et al. Acute improvement of endothelial functions after oral ingestion of isohumulones, bitter components of beer. Biochemical and biophysical research communications. 2017;484(4):740-745. PubMed PMID: 28131837

PubMed Topic Searches

1. PubMed: Xanthohumol randomised trials
2. PubMed: Xanthohumol pharmacokinetics in humans
3. PubMed: Xanthohumol and metabolic syndrome

Back to Table of Contents

Connections

• Hops (Humulus lupulus) — the main page for the plant
• Hops Benefits Deep Dive — the evidence ledger
• Sleep and the Valerian Combination — the sleep trials
• 8-Prenylnaringenin and Menopause — xanthohumol's oestrogenic relative
• Dog Poisoning, Allergy and Beer — safety findings
• Metabolic Syndrome — the cluster of risks studied in animals
• Berberine: AMPK and Metabolic Syndrome — another plant compound acting on AMPK
• Breast Cancer — a cancer type studied in cell work
• Alcohol — why beer is not a xanthohumol source
• Red Clover — another flavonoid-rich herb

Back to Table of Contents